Abbott Laboratories has recently faced a disappointing Q1 performance, causing its shares to stumble. Analysts have reacted to the earnings release with a slew of downgrades, reflecting concerns about the company's future performance. The firm's acquisition of Exact Sciences has raised eyebrows, considerably affecting the firm's financial guidance. Despite the firm's remarkable Q1 revenue growth, margin dropped to 13.9% challenging bullish earnings narratives. The acquisition has reportedly put a drag on the earnings and affected the company's profit outlook for 2026. Abbott has reportedly trimmed its profit forecast for 2026 due to the impact from the Exact Sciences deal. Furthermore, its Q2 earnings guidance was also seen as weak, triggering a 6% tumble in the company's stock. The company's short-term headwinds seem to be outweighing its strategic pipeline strength such as its two-biomarker blood test that improves early cancer detection. Despite the soft figures, the company's shares saw upticks from investment firms. Ninety One UK Ltd and Farther Finance Advisors LLC increased their stakes in Abbott. The company announced that they had completed the acquisition of Exact Sciences.
Abbott Laboratories ABT News Analytics from Tue, 13 Jan 2026 08:00:00 GMT to Sat, 18 Apr 2026 13:00:01 GMT -
Rating -6
- Innovation 0
- Information 4
- Rumor -5
